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general and specifically at the sites of
injury. The principle advantages of
direct laryngoscope are that anaesthesi-
ologists are very experienced in using
the instrument and that it is a highly
effective tool. However, it has the
potential to cause greater cervical spine
movement than indirect laryngoscopy
[4]. Any device that could reduce
cervical spine movement deserves atten-
tion.
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The LMA SupremeTM – a pilot
study
The LMA SupremeTM (Fig. 1; Laryn-
geal Mask Company, Singapore), is a
new extraglottic airway device which
brings together features of both the
LMA ProSealTM (high seal cuff, gastric
access and bite block – to facilitate
ventilation, airway protection and air-
way obstruction, respectively) (Laryn-
geal Mask Company), the LMA
FastrachTM (fixed curve tube and guid-
ing handle – to facilitate insertion and
fixation) (Laryngeal Mask Company)
and the LMA UniqueTM (single use –
prevention of disease transmission)
(Laryngeal Mask Company) [1]. The
new features are that the airway tube
incorporates a drain tube within its
lumen to shorten and straighten its
path, it is oval-shaped to match the
shape of the mouth and to reduce
rotation in the pharynx, the inner cuff
has been strengthened to prevent air-
way obstruction from infolding and
epiglottic fins have been added to
prevent airway obstruction from epi-
glottic downfolding.
With Ethical Committee approval
and informed consent, one of us (AZ)
conducted a pilot study to determine
ease of insertion (number of insertion
attempts and time taken from picking up
the device to the first breath), the
oropharyngeal leak pressure, the fibe-
roptically determined anatomic position,
the intracuff pressure changes and the
frequency of airway trauma and mor-
bidity. Twenty-two patients (ASA I ⁄ II,
aged 18–60) were studied. Induction of
anaesthesia was with fentanyl 0.5–
1 lg.kg)1 and propofol 2–3 mg.kg)1.
The lungs were manually inflated via a
facemask using 2–3% sevoflurane in
oxygen. Additional boluses of propofol
were given as required until the jaw
thrust test was negative. The LMA
Supreme was inserted using a single-
handed rotational technique like the
LMA Fastrach and the cuff inflated to
60 cmH2O. A size 4 mask was used in all
patients as the size 5 was unavailable for
male patients. A gastric tube was inserted
through the drain tube and its position
confirmed by epigastric auscultation.
Maintenance of anaesthesia was with
1.5–2% sevoflurane in nitrous oxide and
oxygen using a circle system with fresh
gas flow of 3 l.min)1. Patients were
initially ventilated and then allowed to
breath spontaneously.
The results are presented in Table 3.
Insertion was easy at the first attempt in
all patients and an effective airway time
of 28 s. Oropharyngeal leak pressure
averaged 37 cmH2O and increased dur-
ing anaesthesia. This was probably
Figure 1 LMA-SupremeTM (Laryngeal Mask Company).
Table 3 Patient demographic details and
results of use of LMA-SupremeTM.
Male ⁄ female 4 ⁄ 18
Age (year) 38 (15)
Weight (kg) 73 (11)
Height (cm) 171 (7)
ASA physical status, I ⁄ II 19 ⁄ 3
Mallampati score I ⁄ II ⁄ III 12 ⁄ 9 ⁄ 1
Duration of anaesthesia (min) 66 (41)
Ease of insertion
(easy, moderate, difficult,
impossible)
22 ⁄ 0 ⁄ 0 ⁄ 0
Effective airway time (s) 28 (5)
Oropharyngeal leak pressure, cmH2O
At 1 min (n = 22) 35 (5)
At 30 min (n = 22) 38 (4)
At 60 min (n = 9) 39 (4)
Intracuff presssure increase,
cmH2O
24 (11)
Data are number or mean (SD).
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related to an increase in intracuff
pressure. The vocal cords were visible
within the view of an endoscope from
the distal end of the airway tube in all
patients. Gastric tube insertion was
successful at the first attempt in all
patients. There was no blood on the
device at removal and no lip, tongue or
mouth trauma. No patient had a sore
throat, dysphagia or dysphonia 2 h
postoperatively.
We conclude that the LMA Supreme
appears to bring together in a single
device many of the best features of the
ProSeal, Fastrach and Unique laryngeal
mask airway devices. Comparative
studies with these and other devices
are currently underway to better deter-
mine the safety and efficacy of the
LMA Supreme and to help define its
role in anaesthesia and emergency
medicine.
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Corporate manslaughter
The Corporate Manslaughter and Cor-
porate Homicide Act 2007 [1] received
Royal Assent on 26 July 2007, and
comes into force on the 6 April 2008,
after which manslaughter will no long-
er be necessarily considered a crime
that only a single individual can com-
mit. The Act has ramifications for
anaesthetists as employees of a corpo-
rate body (that is, an NHS Trust),
particularly those involved in senior
management.
The legislation was introduced in
response to increasing recognition by
the courts of the role that poor organi-
sation and management can play in the
delivery of care which results in a
potentially avoidable death, and as such,
strengthens the ongoing drive towards
improving patient safety. In the medical
setting, the offence of corporate man-
slaughter will be committed when a
hospital Trust owes a duty of providing
reasonable, safe care for a patient or
employee, but breaches that duty
through gross mismanagement, causing
the patient’s (or the employee’s) death
[2].
The case of two junior orthopaedic
surgeons from Southampton University
Hospitals NHS Trust, who were given
suspended sentences after the death of a
31-year man from toxic shock syn-
drome following elective knee surgery,
is instructive as to the offence the new
Act encompasses. The prosecution
rested on a corporate failure by the
hospital to supervise the two doctors,
and the hospital itself was successfully
prosecuted under the Health and Safety
at Work Act 1974, and fined £100 000
[3].
To convict a Trust, the prosecution
has to prove that ‘senior management’
failed to take reasonable care, at a
standard far below what could reason-
ably have been expected of the Trust in
the circumstances. Senior management
is defined as ‘persons who play signif-
icant roles in (i) the making of decisions
about how the whole or a substantial
part of the organisation’s activities are to
be managed or organised, or (ii) the
actual managing or organising of the
whole or a substantial part of those
activities’. This might include anaesthe-
tists who are Lead Clinicians, Clinical
Directors, Divisional Directors or Med-
ical Directors, but may also involve
anaesthetists who are members of
organisational bodies of a Trust, for
example, equipment or drugs commit-
tees, appointment committees or train-
ing committees.
Anaesthetists in senior management
positions may draw comfort from the
fact that the Government expects the
Act to be used only in the most serious
cases, but must appreciate the impor-
tance attached to health and safety
legislation and risk management by the
Act when developing Trust policies,
particularly the supervision and training
of junior staff to whom a duty of patient
care may be delegated [4]. Furthermore,
anaesthetists should undertake to inform
senior management of practices that
they currently consider to fall far below
an acceptable standard of care, in order
that potential liability under the Act is
avoided.
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Drug incompatibility reaction
with use of fluorescein during
anaesthesia
We report a potentially dangerous drug
incompatibility reaction between
Robinul-Neostigmine (Anpharm Ltd,
Tipperary, Ireland) and intravenous
fluorescein. This occurred during an
anaesthetic for confocal endoscopy,
a relatively new technique which
involves the administration of fluores-
cein to facilitate image capture by a laser
fluorescence microscope viewing the
enteral mucosa. During a standard
anaesthetic with propofol induction,
neuromuscular blockade with atracuri-
um, and intermittent positive pressure
ventilation using isoflurane in an oxy-
gen and air intravenous fluorescein 10%
5 ml (Martindale Pharmaceuticals,
Romford, UK) was given via the side
port of a cannula through which was
running a normal saline fluid bolus. At
the conclusion of the procedure,
Correspondence Anaesthesia, 2008, 63, pages 202–213
.....................................................................................................................................................................................................................
210  2008 The Association of Anaesthetists of Great Britain and Ireland
